Piramal Pharma · NSE: PPLPHARMA · BSE: 543635
Q4 FY26 results · Jan–Mar 2026
Piramal Pharma reported revenue from operations of ₹2,751.77 crore (down 0.1% from Q4 FY25) and net loss of ₹8.82 crore for Q4 FY26 (Jan–Mar 2026), on a consolidated basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,751.77 | 2,754.07 | −0.1% | 2,139.87 | +28.6% |
| Other income | 46.06 | 42.03 | +9.6% | 43.24 | +6.5% |
| Total income | 2,797.83 | 2,796.10 | +0.1% | 2,183.11 | +28.2% |
| Profit before share of associates & JVs and tax | 29.43 | 256.58 | −88.5% | (104.12) | Turned profit |
| Share of profit/(loss) of associates & JVs | 13.58 | 16.22 | 10.26 | ||
| Net profit for the period | (8.82) | 153.50 | Turned loss | (136.19) | Loss narrowed |
| EPS, basic (₹) | (0.07) | 1.16 | Turned loss | (1.03) | Loss narrowed |
| Net margin (%) | -0.3 | 5.6 | -6.4 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,489.06 | 1,689.80 | −11.9% | 1,195.81 | +24.5% |
| Other income | 183.69 | 39.51 | +364.9% | 96.15 | +91.0% |
| Total income | 1,672.75 | 1,729.31 | −3.3% | 1,291.96 | +29.5% |
| Profit before tax | 331.85 | 364.36 | −8.9% | 154.93 | +114.2% |
| Net profit for the period | 261.63 | 277.27 | −5.6% | 128.91 | +103.0% |
| EPS, basic (₹) | 1.97 | 2.09 | −5.7% | 0.97 | +103.1% |
| Net margin (%) | 17.6 | 16.4 | 10.8 |
Consolidated
- Filed with BSE
- 28 Apr 2026, 21:41 IST
- Board meeting
- 28 Apr 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 28 Apr 2026, 21:41 IST
- Board meeting
- 28 Apr 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE